Figure 5
(A) 4T1 and MDA-MB-231 cells were treated with 0, 10 and 20 µg/ml lobaplatin. (B) 4T1 and MDA-MB-231 cells were treated with microwave hyperthermia at 37, 39, 41 and 43°C for 1 h. (C) 4T1 and MDA-MB-231 cells were treated in either the absence or presence of lobaplatin (10 μg/ml) or at an indicated temperature. Twenty-four hours later, P-mTOR, mTOR, P-AMPK, AMPK, P-P70S6K, P-AKT, AKT, P-ERK, P-P38, P-JNK and JNK were detected by Western blot analysis. β-actin was used to confirm that the proteins equal in each lane. Means and standard deviations in the bar charts were from three independent experiments.
The PI3K/AKT/mTOR pathway was suppressed and the JNK signaling pathway of 4T1 and MDA-MB-231 cells was activated by lobaplatin, microwave hyperthermia and combination therapy

(A) 4T1 and MDA-MB-231 cells were treated with 0, 10 and 20 µg/ml lobaplatin. (B) 4T1 and MDA-MB-231 cells were treated with microwave hyperthermia at 37, 39, 41 and 43°C for 1 h. (C) 4T1 and MDA-MB-231 cells were treated in either the absence or presence of lobaplatin (10 μg/ml) or at an indicated temperature. Twenty-four hours later, P-mTOR, mTOR, P-AMPK, AMPK, P-P70S6K, P-AKT, AKT, P-ERK, P-P38, P-JNK and JNK were detected by Western blot analysis. β-actin was used to confirm that the proteins equal in each lane. Means and standard deviations in the bar charts were from three independent experiments.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept